The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
Akoustis Technologies shares are trading higher Tuesday after the company announced it has received an additional purchase order for $13 million from an existing customer. Here's a look at what's going on:
